Crossmark

Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy

Crossref DOI link: https://doi.org/10.1038/s41598-024-80283-8

Published Online: 2024-11-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kumar, Manish https://orcid.org/0000-0002-0013-6552
Goswami, Pooja https://orcid.org/0009-0003-5663-9209
Jha, Abhishek https://orcid.org/0000-0001-8650-8822
Manjit, Manjit https://orcid.org/0000-0001-8013-8576
Satpute, Amol Parasram https://orcid.org/0009-0008-9235-758X
Koch, Biplob https://orcid.org/0000-0001-9093-7793
Mishra, Brahmeshwar https://orcid.org/0000-0002-8608-2611
License Information

Text and Data Mining valid from 2024-11-24

Version of Record valid from 2024-11-24
More Information

Article History

Received: 5 June 2024

Accepted: 18 November 2024

First Online: 24 November 2024

Declarations

:

: The authors declare no competing interests.